prikaz prve stranice dokumenta External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis
  Preuzmi
PDF 1.24 MB
Znanstveni rad - Izvorni znanstveni rad
External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis
Canadian Journal of Gastroenterology and Hepatology, 2021 (2021); 9928065. https://doi.org/10.1155/2021/9928065
Gazda, Jakub; Janicko, Martin; Drazilova, Sylvia; Grgurević, Ivica; Filipec Kanižaj, Tajana; Koller, Tomas; Bodorovska, Beatrica; Mijić, Maja; Mikolašević, Ivana; Stromar, Ivana Knežević; Kucinsky, Branislav; Gazda, Matej; Jarcuska, Peter

Citirajte ovaj rad

Gazda, J., Janicko, M., Drazilova, S., Grgurević, I., Filipec Kanižaj, T., Koller, T. ... Jarcuska, P. (2021). External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis. Canadian Journal of Gastroenterology and Hepatology, 2021.. doi: 10.1155/2021/9928065

Gazda, Jakub, et al. "External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis." Canadian Journal of Gastroenterology and Hepatology, vol. 2021, 2021. https://doi.org/10.1155/2021/9928065

Gazda, Jakub, Martin Janicko, Sylvia Drazilova, Ivica Grgurević, Tajana Filipec Kanižaj, Tomas Koller, Beatrica Bodorovska, et al. "External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis." Canadian Journal of Gastroenterology and Hepatology 2021 (2021). https://doi.org/10.1155/2021/9928065

Gazda, J., et al. (2021) 'External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis', Canadian Journal of Gastroenterology and Hepatology, 2021. doi: 10.1155/2021/9928065

Gazda J, Janicko M, Drazilova S, Grgurević I, Filipec Kanižaj T, Koller T, i sur.. External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis. Canadian Journal of Gastroenterology and Hepatology [Internet]. 2021. [pristupljeno 27.12.2024.];2021. doi: 10.1155/2021/9928065

J. Gazda, et al., "External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis", Canadian Journal of Gastroenterology and Hepatology, vol. 2021, 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:373905. [Citirano: 27.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:373905
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis
AutorJakub Gazda
AutorMartin Janicko
AutorSylvia Drazilova
AutorIvica Grgurević
AutorTajana Filipec Kanižaj
AutorTomas Koller
AutorBeatrica Bodorovska
AutorMaja Mijić
AutorIvana Mikolašević
AutorIvana Knežević Stromar
AutorBranislav Kucinsky
AutorMatej Gazda
AutorPeter Jarcuska
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Background. Ursodeoxycholic acid response score (URS) is a prognostic model that estimates the baseline probability of treatment response after 12 months of ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cholangitis (PBC). Aim. To independently evaluate the predictive performance of the URS model. Methods. We used a cohort of Slovak and Croatian treatment-naïve PBC patients to quantify the discrimination ability using the area under receiver operating characteristic curve (AUROC) and its 95% confidence interval (CI). Furthermore, we evaluated the calibration using calibration belts. The primary outcome was treatment response after 12 months of UDCA therapy defined as values of alkaline phosphatase ≤1.67 × upper limit of normal. Results. One hundred and ninety-four patients were included. Median pretreatment age was 56 years (interquartile range 49–62). Treatment response was achieved in 79.38% of patients. AUROC of the URS was 0.81 (95% CI 0.73–0.88) and the calibration belt revealed that response rates were correctly estimated by predicted probabilities. Conclusion. Our results confirm that the URS can be used in treatment-naïve PBC patients for estimating the treatment response probability after 12 months of UDCA therapy.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaCanadian Journal of Gastroenterology and Hepatology
Brojčani podacivol. 2021, 9928065
p-ISSN2291-2789
e-ISSN2291-2797
DOIhttps://doi.org/10.1155/2021/9928065
URN:NBNurn:nbn:hr:184:373905
Datum objave publikacije2021
URL dokumentahttps://www.hindawi.com/journals/cjgh/2021/9928065/
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-09-16 13:14:09